Sound Pharma completes enrollment of Open Label Phase 3 study of SPI-1005 in Meniere’s Disease

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral anti-inflammatory drug, received Breakthrough Therapy Designation (BTD) in late 2025. MD is a complex inner ear disease that involves low to mid frequency hearing loss, tinnitus, vertigo, and dizziness. SPI-1005 is the first drug to receive BTD for MD and for the treatment of sen

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral anti-inflammatory drug, received Breakthrough Therapy Designation (BTD) in late 2025. MD is a complex inner ear disease that involves low to mid frequency hearing loss, tinnitus, vertigo, and dizziness.

SPI-1005 is the first drug to receive BTD for MD and for the treatment of sen